|
|
Last Modified: 9/13/2008  First Published: 8/24/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and under at original diagnosis
|
|
|
|
NCI
|
|
|
|
COG-ARST0321 NCT00068419, ARST0321
|
|
|
|
|
|
|
|
Last Modified: 6/11/2008  First Published: 6/2/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Active
|
|
|
|
40 and over
|
|
|
|
NCI
|
|
|
|
MAYO-030103 MAYO-1395-05, MAY03-1-03, NCT00335504
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Prevention
|
|
|
|
Active
|
|
|
|
16 and over
|
|
|
|
Other
|
|
|
|
23266 KUN 2003-2911, NCT00319007
|
|
|
|
|
|
|
|
Last Modified: 8/13/2008  First Published: 8/18/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Active
|
|
|
|
40 to 79
|
|
|
|
NCI
|
|
|
|
MAYO-03-1-02 MAY03-1-02, NCT00368927
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
06-111 NCT00392665
|
|
|
|
|
|
|
|
First Published: 9/12/2008 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
Other
|
|
|
|
ICORG-06-03 ICORG 06-03 Epi Sunlidac, EUDRACT-2006-006051-12, EU-20876, NCT00632177
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Prevention
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
Other
|
|
|
|
04-099 NCT00299195
|
|
|
|